Vinva Investment Management Boosts Johnson & Johnson Stake

Hedge fund increases holdings in pharmaceutical giant by 33.4% in third quarter

Published on Mar. 8, 2026

Got story updates? Submit your updates here. ›

Vinva Investment Management Ltd, a global investment management firm, increased its stake in Johnson & Johnson (NYSE: JNJ) by 33.4% in the third quarter, according to a recent filing with the Securities and Exchange Commission. The firm now owns 180,971 shares of the pharmaceutical company's stock, valued at $32.9 million.

Why it matters

Johnson & Johnson is one of the world's largest and most diversified healthcare companies, with a strong portfolio of pharmaceutical, medical device, and consumer products. The increased investment by Vinva Investment Management suggests confidence in the company's long-term growth prospects, particularly in its pharmaceutical business which has seen several key drug approvals and pipeline advancements recently.

The details

Vinva Investment Management added 45,352 shares of Johnson & Johnson to its portfolio during the third quarter, bringing its total holdings to 180,971 shares. This represents approximately 0.7% of the firm's total assets under management. The investment comes as Johnson & Johnson has seen its stock price rise over 15% in the past year, driven by the success of its pharmaceutical division and the company's reputation as a defensive, dividend-paying stock.

  • Vinva Investment Management increased its Johnson & Johnson stake in the third quarter of 2026.

The players

Vinva Investment Management Ltd

A global investment management firm that increased its holdings in Johnson & Johnson by 33.4% in the third quarter of 2026.

Johnson & Johnson

A multinational pharmaceutical and consumer goods company that is one of the world's largest healthcare companies.

Got photos? Submit your photos here. ›

The takeaway

Vinva Investment Management's increased stake in Johnson & Johnson underscores the pharmaceutical giant's appeal as a defensive, dividend-paying stock with a strong pipeline of new drugs. The investment highlights the confidence some institutional investors have in Johnson & Johnson's long-term growth prospects.